A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

References

• Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3(11):655–664.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv. 2001;438(1):1.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, Von Mehren M, et al.. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–625.
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247–1253.
   PubMed Web of Science ®Google Scholar
• Call J, Walentas CD, Eickhoff JC et al. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer. 2012;12:90.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al.. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233–238.
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci. 2003;94(4):315–320.
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–5058.
   PubMed Web of Science ®Google Scholar
• Weinstein BI, Joe AK. Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3:448–457.
   PubMedGoogle Scholar
• Siehl J, Thiel E. C-kit, GIST, and imatinib. Recent Results Cancer Res. 2007;176:145–151.
   PubMedGoogle Scholar
• Von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev. 2011;37(4):291–299.
   PubMed Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44:158–162.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894.
   PubMed Web of Science ®Google Scholar
• Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97–112.
   PubMed Web of Science ®Google Scholar
• Rochat B, Fayet A, Widmer N, et al. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J Mass Spectrom. 2008;43:736–752.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–1134.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626.
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097.
   PubMed Web of Science ®Google Scholar
• Yoo C, Ryu M-H, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol. 2010;28(9):1554–1559.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27(19):3141–3147.
   PubMed Web of Science ®Google Scholar
• Eisenhauera EA, Therasseb P, Bogaertsc J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.
   PubMed Web of Science ®Google Scholar
• Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98:2693–2699.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby HK, et al.. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama. 2012;307(12):1265–1272.
   PubMed Web of Science ®Google Scholar
• Casali PG, Cesne AL, Velasco AP et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. JCO.2015.62.4304. Epub ahead of print.
   Google Scholar
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37:75–88.
   PubMed Web of Science ®Google Scholar
• Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39(14):2006.
   PubMed Web of Science ®Google Scholar
• Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9(3):271–281.
   PubMed Web of Science ®Google Scholar
• Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol. 2012;86:1–12.
   PubMed Web of Science ®Google Scholar
• Kim KW, Shinagare AB, Krajewski KM, et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol. 2015;16(2):304–313. doi:10.3348/kjr.2015.16.2.304.
   PubMed Web of Science ®Google Scholar
• Heuchel R, Berg A, Tallquist M, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3’ kinase signaling. Proc Natl Acad Sci USA. 1999;96(20):11410–11415.
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929–2934.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(17715389):3540–3546.
   PubMed Web of Science ®Google Scholar
• Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010;116(1):184–192.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19(4):371–375.
   PubMed Web of Science ®Google Scholar
• McClelland CM, Harocopos GJ, Custer PL. Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol (Auckland, NZ). 2010;4:427–431.
   PubMedGoogle Scholar
• Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol. 2007;86(5):390–393.
   PubMed Web of Science ®Google Scholar
• Deininger MW, O’Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637–1647.
   PubMed Web of Science ®Google Scholar
• Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2):201–206.
   PubMed Web of Science ®Google Scholar
• Lammie A, Drojnak M, Gerald W, et al. Expression of c-kit and kit ligands proteins in normal human tissues. J Histochem Cytochem. 1994;42:1417–1425.
   PubMed Web of Science ®Google Scholar
• Rule SA, O’Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood. 2002;100:3434–3435.
   PubMed Web of Science ®Google Scholar
• Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117:620–622.
   PubMed Web of Science ®Google Scholar
• Vidal D, Puig L, Sureda A, et al. STI571-induced Stevens-Johnson syndrome. Br J Haematol. 2002;119:274–275.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side eVects of imatinib mesylate. J Drugs Dermatol. 5;3:228–231.
   Google Scholar
• Bauer S, Hagen V, Pielken HJ, et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs. 2002;13:847–849.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160–2161.
   PubMed Web of Science ®Google Scholar
• Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455–3456.
   PubMed Web of Science ®Google Scholar
• James C, Trouette H, Marit G, et al. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978–979.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–1937.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate(STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res. 2005;11:12.
   PubMed Web of Science ®Google Scholar
• Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91(6 Suppl):79–80.
   Google Scholar
• Zonder JA, Schiffer CA. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Curr Hematol Malig Rep. 2006;1:141–151.
   PubMedGoogle Scholar
• Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–1423.
   PubMed Web of Science ®Google Scholar
• Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol. 1994;21(2 Suppl 3):3–8.
   PubMed Web of Science ®Google Scholar
• Schallier D1, Trullemans F, Fontaine C, et al. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res. 2009;29(12):5225–5228.
   PubMed Web of Science ®Google Scholar
• Aliberti S, Grignani G, Allione P, et al. Erythrocyte macrocytosis is a rather common apparently uneventful yet unexplained finding in GIST imatinib(I) chronic therapy. Proc ASCO. 2005;827S:9045.
   Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.
   PubMed Web of Science ®Google Scholar
• Motzer RJ1, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar